[Progress of medicine threatened by drug resistance].
D000818:Animals; D000900:Anti-Bacterial Agents / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use; D000962:Antimalarials / Q000494:pharmacology / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects; D003365:Costs and Cost Analysis; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D019049:Developed Countries; D003906:Developing Countries; D004351:Drug Resistance; D004352:Drug Resistance, Microbial; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology / Q000627:therapeutic use; D007891:Leishmania / Q000187:drug effects; D007898:Leishmaniasis, Visceral / Q000188:drug therapy; D010403:Penicillin Resistance; D010965:Plasmodium malariae / Q000187:drug effects; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy / Q000191:economics; D014435:Typhoid Fever / Q000188:drug therapy; D014780:Viruses / Q000187:drug effects; D014944:World Health Organization
D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D000962:Antimalarials; D000995:Antitubercular Agents; D019259:Lamivudine
Les progrès de la médecine menacés par la pharmacorésistance.